News

Ophthalmology Times10h
Harrow enters into agreement with Samsung Bioe for commercial rights to its ophthalmology biosimilar portfolio
Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and ...
Ophthalmology Advisor12h
In Glaucoma, Trabeculectomy Improves Long-Term IOP Better Than Canaloplasty
Trabeculectomy demonstrated greater IOP reduction and a higher complete success rate than canaloplasty.